Balancing benefits and risks in the era of biologics by Adami, G. et al.
This is a repository copy of Balancing benefits and risks in the era of biologics.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/153715/
Version: Published Version
Article:
Adami, G., Saag, K.G., Chapurlat, R.D. et al. (7 more authors) (2019) Balancing benefits 
and risks in the era of biologics. Therapeutic Advances in Musculoskeletal Disease, 11. 
ISSN 1759-720X 
https://doi.org/10.1177/1759720x19883973
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
https://doi.org/10.1177/1759720X19883973 
https://doi.org/10.1177/1759720X19883973
Ther Adv Musculoskel Dis
2019, Vol. 11: 1–6
DOI: 10.1177/ 
1759720X19883973
© The Author(s), 2019.  
Article reuse guidelines:  
sagepub.com/journals-
permissions
Therapeutic Advances in Musculoskeletal Disease
journals.sagepub.com/home/tab 1
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  
(http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission 
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
Biologic treatments have revolutionized the treat-
ment of patients with serious inflammatory auto-
immune diseases and, more recently, with severe 
osteoporosis. Biologics are defined as substances 
produced by living organisms used in the preven-
tion, diagnosis, or treatment of cancer, immune-
mediated diseases, and other diseases. Biological 
drugs include antibodies and interleukins. These 
substances with specific targets are also called 
biologic agents, biological response modifiers, or 
biologic disease-modifying antirheumatic drugs 
(bDMARDs) for rheumatic disease treatment.1
In chronic inflammatory rheumatic, skin and gas-
trointestinal (GI) diseases, the benefits of biolog-
ics have been largely demonstrated in patients 
with severe disease. Biologics have been demon-
strated in randomized controlled trials (RCTs) 
and in daily practice to significantly attenuate dis-
ease progression, by reducing pain and swelling, 
joint damage, skin and GI lesions, and by improv-
ing health-related quality of life of arthritis, skin 
disease and GI inflammation.2,3 The list of bio-
logics beyond anti-tumor necrosis factor (TNF) 
in these conditions is rapidly increasing, with the 
development of new antibodies directed against 
interleukins (ILs), such as antibodies against 
IL-6, IL-17 and IL-23 in inflammatory rheumatic 
diseases. Biologics used to treat rheumatic chronic 
arthritis disorders may also have primarily cellular 
targets, for example, abatacept interferes with the 
activation of T cells and rituximab binds to the 
protein CD20 on the surface of B cells inducing/
triggering B cell death.
In osteoporosis, monoclonal antibodies have been 
developed against the receptor activator of the 
nuclear factor kappa-B ligand (RANKL)4 and 
recently against sclerostin to reduce the risk of 
vertebral and nonvertebral fractures.5
Rheumatologists have been utilizing biologics for 
use in inflammatory rheumatic disease for over 
20 years, starting with anti-TNFs, and with deno-
sumab in osteoporosis for nearly 10 years.
However, in RCTs and postmarketing surveys, it 
has become clear that such potent biologic treat-
ments can also result in serious adverse events, 
more commonly than placebo and standard non-
biologic treatments.
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Therefore, risk minimization strategies have been 
implemented allowing patients to receive the 
greatest benefits from biologic drugs, despite their 
potential risks. The purpose of our review is to 
advise clinicians on how to consider and integrate 
evidence on the benefit–risk ratio of biologics in 
daily practice.
We have selected the example of anti-TNFs 
because they are the first and most frequently pre-
scribed biologics in inflammatory rheumatic dis-
eases. In osteoporosis, we also have reviewed 
denosumab, the most commonly prescribed bio-
logic for fracture prevention.
The example of anti-TNFs in inflammatory 
rheumatic, skin and GI diseases
In addition to their tremendous efficacy, anti-
TNFs have potential side effects, which are listed 
in Table 1 together with potential approaches to 
risk minimization.
One of the first examples comes from the anti-
TNF infliximab. Immediately after its introduc-
tion, an increased incidence of tuberculosis was 
first detected.8 The introduction of rigorous 
measures to screen patients for latent tuberculosis 
or disease in all patients before starting anti-TNF 
has decreased the incidence of tuberculosis in 
rheumatic patients.9 This is a striking example of 
a serious side effect that can be mitigated effec-
tively by physicians. In high-risk patients, risks 
and benefits should be reviewed very carefully. 
For example, in daily practice, anti-TNFs are not 
prescribed in patients with grade 3 or 4 conges-
tive heart failure, and in line with that, congestive 
heart failure is very seldom observed in our 
patients.
Clinicians have made progress in preventing, mon-
itoring for, and managing the major adverse events 
associated with anti-TNFs and other biologics. 
Fundamental to this strategy of risk minimization 
has been a refinement of our knowledge on the 
pathophysiology of inflammatory cytokines.10
Most of the available data related to the safety of 
anti-TNFs are derived from clinical trials. RCTs 
provide the best quality evidence for efficacy and 
are required for market approval; however, they 
are often too small, too short in duration, and 
performed in patients who are too healthy (healthy 
subject bias)11 to adequately define the full risk of 
such drugs. Observational studies, which are con-
ducted on large populations, can help ascertain 
Table 1. Potential adverse events of anti-TNFs.
Types of events Potential approaches to risk mitigation
Infections Pretreatment screening,
Inform patients and practitioners to monitor for infections
Flu and anti-pneumococcal immunization
Temporarily stop treatment or consider alternatives at first signs of 
infections
Temper/stop glucocorticoid use
Inform patients and practitioners, and advise to seek medical attention 
if there are signs or symptoms of severe infection
Congestive heart failure Exclude patients with New York Heart Association class III and IV
Demyelinating diseases Exclude patients with a potential diagnosis of demyelinating disease
Drug-induced systemic lupus 
erythematosus
Measure antibody titer during follow up in case of suspicion
Injection site reactions Eventual change to other TNF-blockers or other biologics
Flare or induction of psoriasis Consider switch to another class of biologics or to a small-molecule-
based disease-modifying drugs, such as a JAK inhibitor6,7
Autoantibodies development Measure antibody titer during follow up
Pregnancy and breastfeeding Use pegylated TNF-blocker
TNF, tumor necrosis factor.
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the safety of medications. Sources such as the 
United States Food and Drugs Administration 
(US FDA) MedWatch and disease registries (e.g. 
the National Database Registry of Rheumatoid 
Arthritis and CORRONA) have contributed sig-
nificantly to identify important safety issues with 
anti-TNFs. Nevertheless, methodological limita-
tions (confounding by indication, patient drop-
out, switching therapies, and limited control 
populations) must be considered when interpret-
ing observational data of therapeutic safety. 
Clinicians must individualize the infection risk 
assessment not only on the basis of the specific 
anti-TNFs used or the expected duration of ther-
apy, but also by taking into account the baseline 
risk susceptibility of a given patient.12
In patients with autoimmune inflammatory rheu-
matic diseases, immunosuppressive therapy 
increases the risk of infections. Several recom-
mendations for minimizing the risk of infections 
have been proposed.13 Screening for latent tuber-
culosis infection is recommended and includes 
medical history for risk factors, interferon-J 
release assay, tuberculin skin test and baseline 
chest radiograph.9 In addition to screening for 
latent tuberculosis and infection followed by 
anti-tuberculosis therapy if appropriate,10,14,15 
screening for chronic hepatitis B virus infection 
and HIV is also recommended.16 Antiviral 
prophylaxis may be warranted for individuals 
who are positive for hepatitis B surface antigen.17 
Vaccinations, ideally, should be administered 
during the remission phase of diseases and, in 
the best case scenario, prior to the initiation of 
immunosuppression. Live-virus vaccines (e.g. 
varicella-zoster vaccine or measles-mumps-
rubella combined vaccine) may be contraindi-
cated in people receiving anti-TNFs, although 
additional data are needed before definitive rec-
ommendations can be made. In contrast, nonlive 
vaccines (e.g. influenza and pneumococcal, teta-
nus toxoid, human papilloma virus) can be safely 
administered and should be strongly recom-
mended with anti-TNF therapy. Vaccinations in 
high-risk and pediatric populations should be 
administered on a case-by-case basis. Caregivers 
of patients on anti-TNFs should follow national 
vaccination schedules, with the exception of the 
oral poliomyelitis vaccine.13
Anti-TNFs were traditionally contraindicated 
during pregnancy and lactation, mostly because 
of a lack of safety data; however, in the last few 
years, encouraging data support the use of some 
anti-TNFs in pregnant women with arthritis, 
leading to the change of the label in some coun-
tries. Indeed, a pharmacokinetic study demon-
strated the lack of placental transfer of the 
molecule in pregnant women.18,19 These findings 
reassured the scientific community and opened a 
new perspective for pregnant women that, so far, 
were not treated adequately.
With the introduction of new non-anti-TNFs, 
new adverse effects have been reported. For 
example, IL-6 inhibition increases the risk of GI 
perforation.20 IL-17 inhibition is burdened by an 
increased rate of mucocutaneous candidiasis,21 
can exacerbate inflammatory bowel diseases22 
and a higher incidence of suicide has been 
reported with the use of brodalumab.23 Another 
example comes from IL12/IL23 inhibition that 
likely increases the risk of reversible posterior leu-
koencephalopathy syndrome.24
The example of denosumab in osteoporosis
Denosumab was the first biologic used for the 
prevention of fractures in high-risk patients.
It increases bone mineral density (BMD) and 
decreases the risk of vertebral and nonvertebral frac-
tures, including hip fractures. A large population-
based cohort study showed that denosumab and 
zoledronic acid have comparable clinical safety 
and effectiveness with regard to the risk of serious 
infection, cardiovascular (CV) diseases, and oste-
oporosis fractures within 365 days after initiation 
of these medications.25
In the past decade we have seen an increasing fear 
of rare adverse events related to antiresorptive 
drugs, namely osteonecrosis of the jaw and atypi-
cal femoral fractures.26,27
In Table 2 we show the potential adverse events 
related to denosumab treatment and potential 
approaches to risk mitigation.
A new biologic that has been recently approved in 
the US, South Korea, Canada, Australia and 
Japan, but not yet in Europe, for the treatment of 
osteoporosis is romosozumab, a potent bone ana-
bolic agent with some antiresorptive properties.5 
Romosozumab has profound effects on BMD 
and has been shown to lower vertebral and clini-
cal fracture risk compared with placebo, and even 
with the active comparator alendronate.28 This 
was shown in patients who are at particularly high 
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risk for subsequent fractures, because of the com-
bination of low bone mass (reflected by low BMD 
by dual-energy X-ray absorptiometry) and low 
bone quality (reflected by the presence of vertebral 
fractures).29 In contrast to the placebo-controlled 
study, in a head-to-head comparison with alen-
dronate, there was a 0.5% risk difference in myo-
cardial infarction and stroke.28 With regulatory 
approval of this new drug for patients with high-
risk fractures, there is now a need for new risk 
minimization strategies around these potential 
adverse events. For example, excluding those 
patients with a recent CV event, past major 
ischemic events, and possibly those with a very 
high Framingham CV risk score might be appro-
priate with this drug; however, the CV risk 
remained low with the use of romosozumab and, 
as noted, was not different from that of placebo.
It is very useful that regulatory agencies try to 
optimize the approval of new drugs, based on 
their efficacy and safety; however, the patient 
voice is also critical. We are living in the days of 
shared decision-making, and we can imagine 
that making treatment decisions around a 
slightly higher, but relevant CV risk might be 
different in patients with one or more painful 
and disabling fractures than in patients with 
only a low T score.
Conclusion
After more than a decade of experience with bio-
logics in inflammatory rheumatic, skin, and GI 
diseases and osteoporosis, the benefit–risk ratio of 
many biologics is generally considered favorable 
for most of patients with serious inflammatory 
arthritis or with severe osteoporosis at high frac-
ture risk. Importantly, we have learned how to 
reduce the risk with the use of our most com-
monly used biologics. For newer biologics in 
osteoporosis, such as romosozumab, additional 
risk mitigation strategies are proposed that could 
offer similarly favorable benefit–risk ratios for 
those at the highest risk of fractures.
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